XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ May 14, 2024 7:30am EDT
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities May 09, 2024 7:30am EDT
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Apr 30, 2024 7:30am EDT
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) Apr 25, 2024 7:30am EDT
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. Mar 19, 2024 4:05pm EDT
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value Mar 08, 2024 7:30am EST
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right Feb 16, 2024 8:00am EST
